COG5-CDG: Expanding the clinical spectrum

Daisy Rymen, Liesbeth Keldermans, Valérie Race, Luc Régal, Nicolas Deconinck, Carlo Dionisi-Vici, Cheuk Wing Fung, Luisa Sturiale, Claire Rosnoblet, François Foulquier, Gert Matthijs, Jaak Jaeken

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The Conserved Oligomeric Golgi (COG) complex is involved in the retrograde trafficking of Golgi components, thereby affecting the localization of Golgi glycosyltransferases. Deficiency of a COG-subunit leads to defective protein glycosylation, and thus Congenital Disorders of Glycosylation (CDG). Mutations in subunits 1, 4, 5, 6, 7 and 8 have been associated with CDG-II. The first patient with COG5-CDG was recently described (Paesold-Burda et al. Hum Mol Genet 2009; 18:4350-6). Contrary to most other COG-CDG cases, the patient presented a mild/moderate phenotype, i.e. moderate psychomotor retardation with language delay, truncal ataxia and slight hypotonia. Methods. CDG-IIx patients from our database were screened for mutations in COG5. Clinical data were compared. Brefeldin A treatment of fibroblasts and immunoblotting experiments were performed to support the diagnosis. Results and conclusion. We identified five new patients with proven COG5 deficiency. We conclude that the clinical picture is not always as mild as previously described. It rather comprises a broad spectrum with phenotypes ranging from mild to very severe. Interestingly, on a clinical basis some of the patients present a significant overlap with COG7-CDG, a finding which can probably be explained by subunit interactions at the protein level.

Original languageEnglish
Article number94
JournalOrphanet Journal of Rare Diseases
Volume7
Issue number1
DOIs
Publication statusPublished - 2012

Fingerprint

Congenital Disorders of Glycosylation
Language Development Disorders
Viverridae
Phenotype
Brefeldin A
Glycosyltransferases
Mutation
Muscle Hypotonia
Golgi Apparatus
Ataxia
Glycosylation
Immunoblotting
Fibroblasts
Databases
Proteins

Keywords

  • CDG-II
  • COG5
  • Conserved oligomeric golgi complex
  • Glycan analysis
  • Glycosylation
  • Trafficking

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

Rymen, D., Keldermans, L., Race, V., Régal, L., Deconinck, N., Dionisi-Vici, C., ... Jaeken, J. (2012). COG5-CDG: Expanding the clinical spectrum. Orphanet Journal of Rare Diseases, 7(1), [94]. https://doi.org/10.1186/1750-1172-7-94

COG5-CDG : Expanding the clinical spectrum. / Rymen, Daisy; Keldermans, Liesbeth; Race, Valérie; Régal, Luc; Deconinck, Nicolas; Dionisi-Vici, Carlo; Fung, Cheuk Wing; Sturiale, Luisa; Rosnoblet, Claire; Foulquier, François; Matthijs, Gert; Jaeken, Jaak.

In: Orphanet Journal of Rare Diseases, Vol. 7, No. 1, 94, 2012.

Research output: Contribution to journalArticle

Rymen, D, Keldermans, L, Race, V, Régal, L, Deconinck, N, Dionisi-Vici, C, Fung, CW, Sturiale, L, Rosnoblet, C, Foulquier, F, Matthijs, G & Jaeken, J 2012, 'COG5-CDG: Expanding the clinical spectrum', Orphanet Journal of Rare Diseases, vol. 7, no. 1, 94. https://doi.org/10.1186/1750-1172-7-94
Rymen, Daisy ; Keldermans, Liesbeth ; Race, Valérie ; Régal, Luc ; Deconinck, Nicolas ; Dionisi-Vici, Carlo ; Fung, Cheuk Wing ; Sturiale, Luisa ; Rosnoblet, Claire ; Foulquier, François ; Matthijs, Gert ; Jaeken, Jaak. / COG5-CDG : Expanding the clinical spectrum. In: Orphanet Journal of Rare Diseases. 2012 ; Vol. 7, No. 1.
@article{10dee5ce842c42f0aef91ea86f978a19,
title = "COG5-CDG: Expanding the clinical spectrum",
abstract = "Background: The Conserved Oligomeric Golgi (COG) complex is involved in the retrograde trafficking of Golgi components, thereby affecting the localization of Golgi glycosyltransferases. Deficiency of a COG-subunit leads to defective protein glycosylation, and thus Congenital Disorders of Glycosylation (CDG). Mutations in subunits 1, 4, 5, 6, 7 and 8 have been associated with CDG-II. The first patient with COG5-CDG was recently described (Paesold-Burda et al. Hum Mol Genet 2009; 18:4350-6). Contrary to most other COG-CDG cases, the patient presented a mild/moderate phenotype, i.e. moderate psychomotor retardation with language delay, truncal ataxia and slight hypotonia. Methods. CDG-IIx patients from our database were screened for mutations in COG5. Clinical data were compared. Brefeldin A treatment of fibroblasts and immunoblotting experiments were performed to support the diagnosis. Results and conclusion. We identified five new patients with proven COG5 deficiency. We conclude that the clinical picture is not always as mild as previously described. It rather comprises a broad spectrum with phenotypes ranging from mild to very severe. Interestingly, on a clinical basis some of the patients present a significant overlap with COG7-CDG, a finding which can probably be explained by subunit interactions at the protein level.",
keywords = "CDG-II, COG5, Conserved oligomeric golgi complex, Glycan analysis, Glycosylation, Trafficking",
author = "Daisy Rymen and Liesbeth Keldermans and Val{\'e}rie Race and Luc R{\'e}gal and Nicolas Deconinck and Carlo Dionisi-Vici and Fung, {Cheuk Wing} and Luisa Sturiale and Claire Rosnoblet and Fran{\cc}ois Foulquier and Gert Matthijs and Jaak Jaeken",
year = "2012",
doi = "10.1186/1750-1172-7-94",
language = "English",
volume = "7",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - COG5-CDG

T2 - Expanding the clinical spectrum

AU - Rymen, Daisy

AU - Keldermans, Liesbeth

AU - Race, Valérie

AU - Régal, Luc

AU - Deconinck, Nicolas

AU - Dionisi-Vici, Carlo

AU - Fung, Cheuk Wing

AU - Sturiale, Luisa

AU - Rosnoblet, Claire

AU - Foulquier, François

AU - Matthijs, Gert

AU - Jaeken, Jaak

PY - 2012

Y1 - 2012

N2 - Background: The Conserved Oligomeric Golgi (COG) complex is involved in the retrograde trafficking of Golgi components, thereby affecting the localization of Golgi glycosyltransferases. Deficiency of a COG-subunit leads to defective protein glycosylation, and thus Congenital Disorders of Glycosylation (CDG). Mutations in subunits 1, 4, 5, 6, 7 and 8 have been associated with CDG-II. The first patient with COG5-CDG was recently described (Paesold-Burda et al. Hum Mol Genet 2009; 18:4350-6). Contrary to most other COG-CDG cases, the patient presented a mild/moderate phenotype, i.e. moderate psychomotor retardation with language delay, truncal ataxia and slight hypotonia. Methods. CDG-IIx patients from our database were screened for mutations in COG5. Clinical data were compared. Brefeldin A treatment of fibroblasts and immunoblotting experiments were performed to support the diagnosis. Results and conclusion. We identified five new patients with proven COG5 deficiency. We conclude that the clinical picture is not always as mild as previously described. It rather comprises a broad spectrum with phenotypes ranging from mild to very severe. Interestingly, on a clinical basis some of the patients present a significant overlap with COG7-CDG, a finding which can probably be explained by subunit interactions at the protein level.

AB - Background: The Conserved Oligomeric Golgi (COG) complex is involved in the retrograde trafficking of Golgi components, thereby affecting the localization of Golgi glycosyltransferases. Deficiency of a COG-subunit leads to defective protein glycosylation, and thus Congenital Disorders of Glycosylation (CDG). Mutations in subunits 1, 4, 5, 6, 7 and 8 have been associated with CDG-II. The first patient with COG5-CDG was recently described (Paesold-Burda et al. Hum Mol Genet 2009; 18:4350-6). Contrary to most other COG-CDG cases, the patient presented a mild/moderate phenotype, i.e. moderate psychomotor retardation with language delay, truncal ataxia and slight hypotonia. Methods. CDG-IIx patients from our database were screened for mutations in COG5. Clinical data were compared. Brefeldin A treatment of fibroblasts and immunoblotting experiments were performed to support the diagnosis. Results and conclusion. We identified five new patients with proven COG5 deficiency. We conclude that the clinical picture is not always as mild as previously described. It rather comprises a broad spectrum with phenotypes ranging from mild to very severe. Interestingly, on a clinical basis some of the patients present a significant overlap with COG7-CDG, a finding which can probably be explained by subunit interactions at the protein level.

KW - CDG-II

KW - COG5

KW - Conserved oligomeric golgi complex

KW - Glycan analysis

KW - Glycosylation

KW - Trafficking

UR - http://www.scopus.com/inward/record.url?scp=84879857014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879857014&partnerID=8YFLogxK

U2 - 10.1186/1750-1172-7-94

DO - 10.1186/1750-1172-7-94

M3 - Article

C2 - 23228021

AN - SCOPUS:84879857014

VL - 7

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 94

ER -